Yuanting Zhao1, Qiande Liao, Yong Zhu, Haitao Long. 1. Department of Orthopedics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410078, People's Republic of China.
Abstract
BACKGROUND: Endothelin-1 (ET-1) participates in a wide range of cancer-relevant processes including cell proliferation, inhibition of apoptosis, matrix remodeling, bone deposition, and metastases. Although ET-1 reportedly promotes osteosarcoma (OS) cell invasion, suggesting an important role of ET-1 in OS metastasis, the role of ET-1 in OS remains unclear. QUESTION/PURPOSES: We asked whether (1) ET-1 expression is associated with the malignancy of OS, (2) ET-1 enhances the cell invasion ability of OS, and (3) ET-1 promotes OS cell survival against apoptotic stress. METHODS: We cultured primary OS specimens from 22 patients with Stages II (OS-II) and III (OS-III) in real-time quantitative RT-PCR and ELISA to compare ET-1 expression. We used Transwell(®) cell invasion assays (in triplicate) to assess the invasion ability of cells in the presence or absence of exogenous ET-1 and/or ET receptor antagonists. We compared cell apoptosis rate among the cells treated with cisplatin in the presence or absence of exogenous ET-1 and/or ET receptor antagonists. We used OS cell line MG-63 in all experiments as a reference. RESULTS: Real-time quantitative RT-PCR and ELISA showed OS-III cells had greater ET-1 expression than OS-II cells at the mRNA and the secreted protein levels. Transwell(®) cell invasion assays showed OS-III cells had a greater migrated cell number than OS-II cells, which could be abrogated by ET(A) receptor antagonist BQ123 (100 pmol/L), but not ET(B) receptor antagonist BQ788 (1 μmol/L); exogenous ET-1 dose-dependently promoted OS cell migration, which could be inhibited by BQ123 (100 pmol/L). Cisplatin (10 nmol/L) induced less apoptosis in OS-III cells than in OS-II cells; exogenous ET-1 dose-dependently promoted OS cell survival against cisplatin-induced apoptosis; both effects were reversed by BQ123 (1 μmol/L), but not BQ788 (1 μmol/L). CONCLUSIONS: Increased ET-1 expression appears to be associated with increased malignancy of OS. ET-1 promotes OS cell invasion and survival against cisplatin-induced apoptosis through the ET(A) receptor. CLINICAL RELEVANCE: The ET-1/ET(A) pathway may represent an important target for treating OS, because blocking the ET(A) receptor with a selective antagonist can inhibit OS cell invasion and potentiate a chemotherapeutic agent's effect on OS.
BACKGROUND:Endothelin-1 (ET-1) participates in a wide range of cancer-relevant processes including cell proliferation, inhibition of apoptosis, matrix remodeling, bone deposition, and metastases. Although ET-1 reportedly promotes osteosarcoma (OS) cell invasion, suggesting an important role of ET-1 in OS metastasis, the role of ET-1 in OS remains unclear. QUESTION/PURPOSES: We asked whether (1) ET-1 expression is associated with the malignancy of OS, (2) ET-1 enhances the cell invasion ability of OS, and (3) ET-1 promotes OS cell survival against apoptotic stress. METHODS: We cultured primary OS specimens from 22 patients with Stages II (OS-II) and III (OS-III) in real-time quantitative RT-PCR and ELISA to compare ET-1 expression. We used Transwell(®) cell invasion assays (in triplicate) to assess the invasion ability of cells in the presence or absence of exogenous ET-1 and/or ET receptor antagonists. We compared cell apoptosis rate among the cells treated with cisplatin in the presence or absence of exogenous ET-1 and/or ET receptor antagonists. We used OS cell line MG-63 in all experiments as a reference. RESULTS: Real-time quantitative RT-PCR and ELISA showed OS-III cells had greater ET-1 expression than OS-II cells at the mRNA and the secreted protein levels. Transwell(®) cell invasion assays showed OS-III cells had a greater migrated cell number than OS-II cells, which could be abrogated by ET(A) receptor antagonist BQ123 (100 pmol/L), but not ET(B) receptor antagonist BQ788 (1 μmol/L); exogenous ET-1 dose-dependently promoted OS cell migration, which could be inhibited by BQ123 (100 pmol/L). Cisplatin (10 nmol/L) induced less apoptosis in OS-III cells than in OS-II cells; exogenous ET-1 dose-dependently promoted OS cell survival against cisplatin-induced apoptosis; both effects were reversed by BQ123 (1 μmol/L), but not BQ788 (1 μmol/L). CONCLUSIONS: Increased ET-1 expression appears to be associated with increased malignancy of OS. ET-1 promotes OS cell invasion and survival against cisplatin-induced apoptosis through the ET(A) receptor. CLINICAL RELEVANCE: The ET-1/ET(A) pathway may represent an important target for treating OS, because blocking the ET(A) receptor with a selective antagonist can inhibit OS cell invasion and potentiate a chemotherapeutic agent's effect on OS.
Authors: A Giaid; Q A Hamid; D R Springall; M Yanagisawa; O Shinmi; T Sawamura; T Masaki; S Kimura; B Corrin; J M Polak Journal: J Pathol Date: 1990-09 Impact factor: 7.996
Authors: M Nakamuta; M Ohashi; S Tabata; Y Tanabe; K Goto; M Naruse; K Naruse; K Hiroshige; H Nawata Journal: Am J Gastroenterol Date: 1993-02 Impact factor: 10.864
Authors: J B Nelson; S P Hedican; D J George; A H Reddi; S Piantadosi; M A Eisenberger; J W Simons Journal: Nat Med Date: 1995-09 Impact factor: 53.440
Authors: Xu Shi-Wen; Yunliang Chen; Christopher P Denton; Mark Eastwood; Elisabetta A Renzoni; George Bou-Gharios; Jeremy D Pearson; Michael Dashwood; Roland M du Bois; Carol M Black; Andrew Leask; David J Abraham Journal: Mol Biol Cell Date: 2004-03-26 Impact factor: 4.138
Authors: S Schweyer; A Soruri; O Meschter; A Heintze; F Zschunke; N Miosge; P Thelen; T Schlott; H J Radzun; A Fayyazi Journal: Br J Cancer Date: 2004-08-02 Impact factor: 7.640
Authors: Clayton M Carey; Raymund Bueno; Daniel A Gutierrez; Christopher Petro; Sara E Lucena; Elda E Sanchez; Julio G Soto Journal: Toxicon Date: 2011-12-13 Impact factor: 3.033